Stay updated on Efficacy of LOU064 in Asthma Patients Clinical Trial
Sign up to get notified when there's something new on the Efficacy of LOU064 in Asthma Patients Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FjbsqK5MUyn6yuudPd7y5XCAXn38.uncropped.jpg&w=3840&q=75)
Latest updates to the Efficacy of LOU064 in Asthma Patients Clinical Trial page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has expanded to include 19 locations and has been updated from revision v2.9.7 to v2.10.0.SummaryDifference0.3%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content related to the study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has recently changed to 'Show less MedlinePlus related topics: Asthma FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Quadruple ( Participant Care Provider Investigator Outcomes Assessor ) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : LOU064 LOU064 100 mg once daily orally Drug : LOU064 100 mg LOU064 100 mg once daily orally administered as two 50 mg capsules Placebo Comparator : Placebo Placebo once daily orally Drug : Placebo Placebo once daily administered orally as capsules Primary Outcome Measures Outcome Measure Measure Description Time Frame Change From Baseline in Pre-dose FEV1 at Week 12 FEV1 (forced expiratory volume in one second) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Pre-dose FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre-dose. The baseline pre-dose FEV1 is defined as the average of the FEV1 measurements performed 45 min and 15 min prior to dosing on Day 1. A positive change from baseline in pre-dose FEV1 is considered a favorable outcome. Change from baseline in pre-dose FEV1 was analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment*visit interaction and baseline pre-dose FEV1. A weakly informative prior was considered for the placebo response. Baseline, Week 12'SummaryDifference61%
Stay in the know with updates to Efficacy of LOU064 in Asthma Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of LOU064 in Asthma Patients Clinical Trial page.